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(CVD) risk in patients with non-dialysis chronic kidney
disease (CKD), but it is unclear which regimen is the most
cost-effective. We used the Study of Heart and Renal
Protection (SHARP) CKD-CVD policy model to evaluate the
effect of statins and ezetimibe on quality-adjusted life years
(QALYs) and health care costs in the United States (US) and
the United Kingdom (UK). Net costs below $100,000/QALY
(US) or £20,000/QALY (UK) were considered cost-effective.
We investigated statin regimens with or without ezetimibe
10 mg. Treatment effects on cardiovascular risk were
estimated per 1-mmol/L reduction in low-density
lipoprotein (LDL) cholesterol as reported in the Cholesterol
Treatment Trialists’ Collaboration meta-analysis, and
reductions in LDL cholesterol were estimated for each
statin/ezetimibe regimen. In the US, atorvastatin 40 mg
($0.103/day as of January 2019) increased life expectancy
by 0.23 to 0.31 QALYs in non-dialysis patients with stages
3B to 5 CKD, at a net cost of $20,300 to $78,200/QALY.
Adding ezetimibe 10 mg ($0.203/day) increased life
expectancy by an additional 0.05 to 0.07 QALYs, at a net cost
of $43,600 to $91,500/QALY. The cost-effectiveness ﬁndings
andpolicy implications in theUKwere similar. In summary, in
patients with non-dialysis-dependent CKD, the evidence
suggests that statin/ezetimibe combination therapy is a
cost-effective treatment to reduce the risk of CVD.
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170W ith over 250 million people affected worldwide,CKD is a common disease,1,2 and its prevalence isexpected to increase further with rising levels of
obesity and diabetes and an aging population. In the US,
approximately 7% of adults have stage 3-5 CKD.3 People with
reduced kidney function have increased cardiovascular risk,4,5
which is a key treatment target.
The SHARP trial showed that lowering LDL cholesterol
with a combination of simvastatin 20 mg plus ezetimibe 10
mg daily for about 5 years safely reduced the risk of major
atherosclerotic events (i.e., nonfatal myocardial infarction or
coronary death, nonhemorrhagic stroke, or arterial revascu-
larization procedure) in nondialysis patients with moderate-
to-advanced CKD.6 Subsequently, a large meta-analysis of
individual participant data from 28 trials of statin therapy, or,
in the case of SHARP, statin plus ezetimibe, was coordinated
by the Cholesterol Treatment Trialists’ (CTT) Collaboration.7
This showed that the relative reduction in major vascular
events (i.e., major atherosclerotic event, noncoronary cardiac
death, or hemorrhagic stroke) per 1 mmol/L reduction in
LDL cholesterol ranged from 22% among participants with
estimated glomerular ﬁltration rate (eGFR) of $60 ml/min
per 1.73 m2 to 15% among nondialysis participants with
eGFR <30 ml/min per 1.73 m2, with a trend toward smaller
risk reductions with lower eGFR and no evidence of clinical
efﬁcacy in dialysis patients. By design, SHARP did not assess
the separate clinical effects of ezetimibe, but evidence of the
effects on vascular outcomes of adding ezetimibe to simva-
statin, albeit in patients with an acute coronary syndrome
and without established CKD, has been provided by the
Improved Reduction of Outcomes: Vytorin Efﬁcacy Interna-
tional Trial (IMPROVE-IT).8 In this trial, for each mmol/L
reduction in LDL cholesterol, the relative reduction in
vascular events resulting from ezetimibe was consistent with
that predicted by a meta-analysis of randomized trials of
statin therapy alone.9
Based on all randomized trial evidence, the Kidney Dis-
ease: Improving Global Outcomes (KDIGO) Clinical Practice
Guideline for Lipid Management in CKD recommended use
of a statin or statin/ezetimibe combination for adults $50
years old with an eGFR #60 ml/min per 1.73 m2 who are not
on renal replacement therapy (RRT: chronic dialysis or kidneyKidney International (2019) 96, 170–179
I Schlackow et al.: Cost-effectiveness of statins/ezetimibe in CKD c l i n i ca l i nves t iga t iontransplantation), and a statin alone for other adults with non-
dialysis-dependent CKD.10 The 2018 ACC/AHA Multisociety
Guideline on cholesterol management recommends initiating
statin or statin/ezetimibe combination in $40-year-old CKD
patients with an increased (>7.5%) 10-year risk of athero-
sclerotic cardiovascular disease.11-13 In the UK, the National
Institute for Health and Care Excellence recommends ator-
vastatin 20 mg daily for the primary prevention of cardio-
vascular disease in people with eGFR <60 ml/min per
1.73 m2 and suggests considering a higher dose, and/or
combination with ezetimibe, in more advanced CKD
(e.g., eGFR <30 ml/min per 1.73 m2), for secondary car-
diovascular disease prevention, or when the desired choles-
terol reduction has not been achieved.14,15
Despite these recommendations, it remains unclear which
statin/ezetimibe combination is the most cost-effective treat-
ment in moderate-to-advanced CKD (i.e., offers the greatest
beneﬁts and is affordable). A cost-effectiveness study of 5-year
simvastatin plus ezetimibe treatment in SHARP concluded
that high-intensity generic treatments, rather than more
expensive proprietary treatments, are cost-effective.16 How-
ever, a more pertinent question for health care providers is
the cost-effectiveness of long-term treatments. We used the
SHARP CKD-CVD policy model17 to project lifetime risks of
CVD and CKD progression and the net effects and cost-
effectiveness of long-term statin/ezetimibe treatments in cat-
egories of patients with CKD.
RESULTS
CKD patients
Results are presented only for nondialysis patients, since
there is no clear evidence that LDL cholesterol-lowering
therapy is effective in dialysis patients.7 The mean age of
the 6235 patients in the SHARP study6,18 was 63 years
(SD, 12); 62% were male; 23% had diabetes; and 15% had a
prior history of (noncoronary) vascular disease. There were
2020 participants with stage 3B disease; 2767 with stage
4 disease; and 1448 with stage 5 disease not on dialysis. The
participants’ median 5-year cardiovascular risk ranged from
10% in those with stage 3B to 20% in nondialysis partici-
pants in stage 5, and from 6% to 31% across the 3 cate-
gories of baseline risk (Table 1). Within each stage of CKD,
participants at higher risk at baseline were older and more
likely to have previous vascular disease or diabetes
(Supplementary Table S1).
Effects of statin/ezetimibe treatments
Of the treatments considered, the least potent was ezetimibe
10 mg daily, which reduced LDL cholesterol by 18.5%; the
most potent was atorvastatin 40 mg plus ezetimibe 10 mg
daily, which reduced LDL cholesterol by 60.1%. Atorvastatin
40 mg daily reduced LDL cholesterol by 48% (Supplementary
Table S2). The proportional reductions in risk of major
vascular events with use of ezetimibe 10 mg daily were 8%
(99% conﬁdence interval [CI], 2%, 14%) in stage 3B, 8%
(–1%, 17%) in stage 4, and 8% (–1%, 16%) in stage 5 not onKidney International (2019) 96, 170–179dialysis. The proportional reductions in risk of major vascular
events with use of atorvastatin 40 mg daily were 20% (6%,
33%) in stage 3B, 20% (–3%, 38%) in stage 4, and 19% (–3%,
36%) in stage 5 not on dialysis. The proportional reductions
in risk of major vascular events with use of atorvastatin 40 mg
plus ezetimibe 10 mg daily were 25% (7%, 40%) in stage 3B,
25% (–4%, 45%) in stage 4, and 23% (–3%, 43%) in stage 5
not on dialysis (Supplementary Table S3).
US cost-effectiveness of statin/ezetimibe treatments
In all categories of CKD patients, at current statin/ezetimibe
prices (January 2019), treatment with ezetimibe 10 mg was
both less effective and more expensive than treatment with
atorvastatin 20 mg. Therefore, in health economic jargon,
ezetimibe 10 mg was “dominated” by atorvastatin 20 mg;
rosuvastatin 20 mg was dominated by similarly effective and
slightly cheaper atorvastatin 40 mg; simvastatin 20 mg plus
ezetimibe 10 mg was dominated by atorvastatin 40 mg; and
atorvastatin 20 mg plus ezetimibe 10 mg was dominated by
atorvastatin 40 mg (Supplementary Table S2). Additionally,
atorvastatin 20 mg was projected to produce very similar
health beneﬁts at a similar additional cost per QALY to
atorvastatin 40 mg (Supplementary Table S4). Therefore, we
present results for atorvastatin 40 mg and atorvastatin 40 mg
plus ezetimibe 10 mg only. However, since atorvastatin 20 mg
could be considered a less intensive treatment option, and
ezetimibe 10 mg could be used by patients who cannot
tolerate or do not use a statin-based regimen, we also present
results for these regimens.
Lifetime use of atorvastatin 40 mg is projected to increase
life expectancy by 0.26 years (0.23 QALYs) at a net cost of
$20,300/QALY in patients with stage 3B disease; 0.37 years
(0.31 QALYs) at a net cost of $44,200/QALY in patients with
stage 4 disease; and 0.31 years (0.26 QALYs) at $78,200/QALY
in patients with stage 5 disease not on dialysis. Similarly, it
would increase life expectancy by 0.29 years (0.26 QALYs) at
$38,100/QALY in those at low cardiovascular risk (<10%); by
0.32 years (0.27 QALYs) at $41,000/QALY in those at medium
cardiovascular risk (10%–20%); and by 0.36 years (0.29
QALYs) at $55,000/QALY in those at high cardiovascular risk
($20%) (Table 2). Within each cardiovascular risk group, the
net cost per QALY was lowest for patients in stage 3B and
highest for those in stage 5 not on dialysis, whereas within
each CKD stage, net costs per QALY were similar at all levels
of cardiovascular risk (Supplementary Figure S1). In almost
all subgroups, patients who were younger at treatment initi-
ation were projected to beneﬁt the most but at the highest net
cost per QALY. For example, patients <60 years old were
projected to gain between 0.28 QALYs (if at low risk) and 0.51
QALYs (if at high risk), at a net cost, respectively, of $42,000
to $76,400/QALY; whereas the respective estimates for the
patients $70 years old were 0.13 (low risk) to 0.22 (high risk)
QALYs, at a net cost, respectively, of $10,700 to $42,300/
QALY (Supplementary Table S5).
Adding ezetimibe 10 mg was estimated to provide further
beneﬁts: there were an additional 0.06 years (0.05 QALYs, net171
Table 1 | Characteristics of nondialysis SHARP participants by CKD stage and cardiovascular disease risk at baseline
By CKD stage at baseline By 5-year risk of cardiovascular disease at baseline
CKD stage 3B* CKD stage 4
CKD stage 5,
not on dialysis Low (<10%)
Medium
(10%-20%) High (‡20%)
n[2020 n[2767 n[1448 n[2151 n[2045 n[2039
Age, years 62 (11) 64 (12) 62 (12) 53 (8) 65 (9) 71 (9)
Male 1461 (72%) 1653 (60%) 760 (52%) 1080 (50%) 1337 (65%) 1457 (71%)
Current smoker 271 (13%) 336 (12%) 162 (11%) 219 (10%) 273 (13%) 277 (14%)
Previous vascular disease 283 (14%) 430 (16%) 217 (15%) 43 (2%) 146 (7%) 741 (36%)
Diabetes mellitus 469 (23%) 662 (24%) 293 (20%) 106 (5%) 345 (17%) 973 (48%)
Treated hypertension 1701 (84%) 2389 (86%) 1261 (87%) 1841 (86%) 1751 (85%) 1767 (87%)
Body-mass index, kg/m2 28 (5) 28 (6) 27 (5) 27 (5) 28 (5) 27 (6)
Diastolic blood pressure, mm Hg 80 (13) 79 (13) 80 (12) 82 (12) 80 (12) 77 (13)
Systolic blood pressure, mm Hg 139 (20) 139 (21) 141 (21) 132 (17) 139 (20) 147 (22)
LDL cholesterol, mmol/L 2.9 (0.8) 2.9 (0.8) 2.7 (0.9) 2.9 (0.8) 2.9 (0.9) 2.8 (0.9)
HDL cholesterol, mmol/L 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 1.2 (0.3) 1.1 (0.3) 1.1 (0.3)
Estimated 5-year risk of
cardiovascular disease,
median (IQR)
10% (6%, 18%) 14% (9%, 24%) 20% (11%, 32%) 6% (5%, 8%) 14% (12%, 17%) 31% (24%, 42%)
CKD stage at baseline
CKD stage 3Ba 967 (45%) 649 (32%) 404 (20%)
CKD stage 4 882 (41%) 968 (47%) 917 (45%)
CKD stage 5, not on dialysis 302 (14%) 428 (21%) 718 (35%)
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range; SHARP, Study of Heart and Renal Protection.
Results are shown as mean (SD) or N (%), as appropriate, unless otherwise speciﬁed. Ten participants on kidney transplant at baseline were excluded.
a338 (17%) of participants with CKD stage 3A (eGFR 60-45 ml/min per 1.73 m2).
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cost $58,400/QALY) in stage 4; and 0.07 years (0.06 QALYs,
net cost $91,500/QALY) in stage 5 not on dialysis. There were
an additional 0.06 years (0.06 QALYs, net cost $65,100/QALY)
in low-risk patients; 0.07 years (0.06 QALYs, net cost $56,700/
QALY) in medium-risk patients; and 0.08 years (0.07 QALYs,
net cost $64,400/QALY) in high-risk patients (Table 2). At the
$100,000/QALY cost-effectiveness threshold, atorvastatin 40
mg plus ezetimibe 10 mg would be considered cost-effective
with a >95% probability in all patients except those in
stage 5 not on dialysis (76%) (Figure 1).
Similar to treatment with atorvastatin 40 mg alone, the net
cost per QALY with the combination of atorvastatin 40 mg and
ezetimibe 10mgdaily, compared to atorvastatin 40mgdaily, was
lowest for patients in stage 3B and highest for those in stage 5 not
on dialysis, at each level of risk (Supplementary Figure S1).
Ezetimibe 10 mg daily, compared to no lipid-lowering
treatment, was projected to result in 0.09 extra QALYs in stage
3B, 0.13 extra QALYs in stage 4, and 0.10 extra QALYs in stage 5
not on dialysis, at a net cost, respectively, of $31,000, $50,600,
and $84,200/QALY, and 0.11 extra QALYs in low-risk patients,
0.11 extra QALYs in medium-risk patients, and 0.12 extra
QALYs in high-risk patients at a net cost, respectively, of $50,900,
$48,300, and $58,800/QALY (Supplementary Table S6).
UK cost-effectiveness of statin/ezetimibe treatments
In the UK setting, ezetimibe is now also available at low prices
from generic treatment manufacturers (£0.074/d, January 2019).
The treatment beneﬁts, cost-effectiveness, and policy implica-
tions for different statin/ezetimibe treatments (i.e., atorvastatin
40mg daily and ezetimibe 10mg daily alone and in combination172with a statin) were similar to those in the US (Table 2, Figure 1,
Supplementary Tables S5–S7, Supplementary Figure S1).
Sensitivity analyses
The cost-effectiveness results were only minimally sensitive to
further falls in the price of ezetimibe (Figure 2). If ezetimibe
10 mg were priced at less than $0.323/d (£0.019/d in the UK),
its net cost per QALY would be under $100,000 (£20,000) for
all nondialysis CKD patients.
When analyses were repeated with the annual treatment
costs for RRT assumed similar to those for CKD stage 5 not
on dialysis, the net cost per QALY with statin/ezetimibe
treatments decreased substantially. In the US setting, the net
cost per QALY with atorvastatin 40 mg daily decreased from
$20,300 to $5000 in stage 3B, from $44,200 to $6900 in stage
4, and from $78,200 to $7100 in CKD stage 5 not on dialysis.
The net cost per QALY for atorvastatin 40 mg plus ezetimibe
10 mg daily decreased from $43,600 to $27,500 in stage 3B,
from $58,400 to $20,600 in stage 4, and from $91,500 to
$19,900 in stage 5 not on dialysis. The effect was similar in the
UK setting (Supplementary Table S8).
The net costs per QALY only minimally increased when
potential adverse effects of statin/ezetimibe treatments and
their costs were projected (Supplementary Table S9). Reduced
compliance with treatment was projected to result in lower
health beneﬁts but also lower incremental hospital costs and
did not materially affect the results (Supplementary Table S10).
DISCUSSION
Lowering LDL cholesterol with statin-based treatments
safely reduces cardiovascular risk in patients withKidney International (2019) 96, 170–179
Table 2 | Health beneﬁts and cost-effectiveness of statin-based treatments in moderate-to-advanced nondialysis CKD patients
Category of CKD patient
Atorvastatin 40 mg dailya compared to no LDL-C
lowering treatment
Ezetimibe 10 mg plus atorvastatin 40 mg daily
compared to atorvastatin 40 mg daily
Life-
years
gained
QALYs
gained
Additional
cost per QALYb
Life-
years
gained
QALYs
gained
Additional cost
per QALYb
(A) US health care setting
By CKD stage at baseline
CKD stage 3Bc 0.26 0.23 $20,300 0.06 0.05 $43,600
CKD stage 4 0.37 0.31 $44,200 0.08 0.07 $58,400
CKD stage 5, not on dialysis 0.31 0.26 $78,200 0.07 0.06 $91,500
By 5-year risk of cardiovascular disease at baseline
Low (<10%) 0.29 0.26 $38,100 0.06 0.06 $65,100
Medium (10%-20%) 0.32 0.27 $41,000 0.07 0.06 $56,700
High ($20%) 0.36 0.29 $55,000 0.08 0.07 $64,400
(B) UK health care setting
By CKD stage at baseline
CKD stage 3Bc 0.28 0.25 £3800 0.07 0.06 £12,500
CKD stage 4 0.42 0.33 £10,500 0.09 0.07 £16,000
CKD stage 5, not on dialysis 0.37 0.29 £18,900 0.09 0.07 £23,900
By 5-year risk of cardiovascular disease at baseline
Low (<10%) 0.33 0.29 £7,900 0.08 0.07 £17,800
Medium (10%-20%) 0.36 0.29 £9,400 0.08 0.07 £15,200
High ($20%) 0.40 0.29 £14,200 0.09 0.07 £17,800
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; LDL-C, low-density lipoprotein cholesterol; QALY, quality-adjusted life-year; UK, United Kingdom; US,
United States.
The CKD and cardiovascular risk categories are derived directly from the 6235 moderate-to-advanced non–dialysis-dependent CKD patients in the Study of Heart and Renal
Protection (SHARP).
aAtorvastatin 20 mg daily was projected to produce only slightly smaller health beneﬁts at similar additional cost per QALY to atorvastatin 40 mg daily (see Supplementary
Tables S4 and S7 for detailed results) and could be considered as an alternative less intensive treatment option.
bCosts and outcomes discounted at 3% per annum (US) or 3.5% per annum (UK).
c338 (17%) of participants with CKD stage 3A (eGFR 60–45 ml/min per 1.73 m2).
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nance dialysis, but there is no evidence that such treatment is
effective in dialysis patients.7 We report that under the stan-
dard cost-effectiveness assumptions (i.e., a threshold of
$100,000/QALY [£20,000 to £30,000/QALY in the UK]), low-
cost statin treatments (e.g., atorvastatin 40 mg daily) are cost-
effective in nondialysis CKD patients. Ezetimibe has recently
come off patent in both countries and, at current prices
($0.203/d and £0.074/d, respectively), adding ezetimibe
10 mg to atorvastatin 40 mg daily is a cost-effective option in
nondialysis CKD patients and would thus be the treatment of
choice. The results remain robust across a range of sensitivity
analyses.
Despite the higher net cost per QALY, the ﬁnding that low-
cost generic statins/ezetimibe are cost-effective for primary
prevention of CVD in CKD is consistent with results for the
general population at an increased cardiovascular risk.19,20
Unlike general population estimates, in non–dialysis-
dependent CKD, the net cost per QALY was generally
higher in patients at more advanced CKD stage and/or higher
predicted cardiovascular risk, especially for very low-cost
treatments (e.g., atorvastatin 40 mg or ezetimibe 10 mg at a
lower price). This is driven by reduced life expectancy, higher
end-stage kidney disease risks, and RRT costs, which are
incurred during the gained life expectancy and are substantial
in more advanced CKD. Statin-based treatments would alsoKidney International (2019) 96, 170–179be more cost-effective in patients receiving a kidney trans-
plant, with lower RRT costs in the years after the
transplantation.
The present study builds upon a study by Erickson et al.21
and our ﬁndings support its conclusion that cheaper generic
statins are likely cost-effective in CKD. However, our study
takes a substantially more detailed look into the long-term
effects of individual treatments across categories of CKD
patients. We used the rich individual data from the SHARP
study, which enabled us to present results generalizable to
CKD patients at similar cardiovascular risk and/or CKD stage.
We also used results from the CTT individual participant
meta-analysis of 28 large trials, which provide the best
available estimates for cardiovascular risk reductions with
statin-based treatments at different levels of renal function.7
Linking these with the potency of individual statin/ezeti-
mibe regimens enabled evaluation of the cost-effectiveness of
different regimens reliably.
In the present study, treatment with rosuvastatin 20 mg
was similarly effective but slightly more expensive than
atorvastatin 40 mg (atorvastatin 40 mg is available at
$0.103/d in the US and £0.034/d in the UK, compared to
$0.119/d and £0.077/d, respectively, for rosuvastatin 20 mg).
Small further ﬂuctuations in prices would make rosuvastatin
a cost-effective option. The use of less potent treatments
(e.g., atorvastatin 20 mg or ezetimibe 10 mg alone) achieves173
Figure 1 | Probability of a statin-based treatment to be cost-effective in moderate-to-advanced nondialysis chronic kidney disease (CKD)
patients. Results shown for treatments on the cost-effectiveness frontier (i.e., the most cost-effective treatment for a given value of will-
ingness to pay) within the range of willingness-to-pay values per quality-adjusted life-year (QALY). Typical cost-effectiveness thresholds are
represented with dashed horizontal lines. Atorvastatin 20 mg daily was largely dominated by atorvastatin 40 mg daily and was omitted from
the graph. LDL-C, low-density lipoprotein cholesterol; UK, United Kingdom; US, United States.
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Figure 2 | Cost-effectiveness of adding ezetimibe 10 mg to atorvastatin 40 mg daily for moderate-to-advanced nondialysis chronic
kidney disease (CKD) patients, at different ezetimibe cost. The CKD and cardiovascular risk categories are derived directly from the 6235
moderate-to-advanced non–dialysis-dependent CKD patients in the Study of Heart and Renal Protection (SHARP). Typical cost-
effectiveness thresholds are represented with dashed horizontal lines. *A total of 338 (17%) participants with CKD stage 3A (estimated
glomerular ﬁltration rate [eGFR] 60–45 ml/min per 1.73 m2). At the $100,000/quality-adjusted life-year [QALY] threshold in the United States
(US) (a), ezetimibe 10 mg daily becomes cost-effective in all categories of patients when its price reaches $0.323/d. At the £20,000/QALY
threshold in the United Kingdom (UK) (b), ezetimibe 10 mg daily becomes cost-effective in all categories of patients when its price reaches
£0.019/d.
I Schlackow et al.: Cost-effectiveness of statins/ezetimibe in CKD c l i n i ca l i nves t iga t ionsmaller cardiovascular beneﬁts. In general, statin/ezetimibe
treatments that achieve larger reductions in LDL cholesterol
are expected to achieve greater health beneﬁts and, if avail-
able at low cost, be cost-effective. In the present analyses, we
did not consider more potent statin treatments such as
atorvastatin 80 mg and rosuvastatin 40 mg, since they are not
routinely used in CKD patients due to safety concerns.Kidney International (2019) 96, 170–179However, if future evidence indicates safety of these regimens
in CKD, our analysis suggests that, if available at low cost,
they will be cost-effective.
Several limitations of the present analyses should be
acknowledged. First, SHARP included only CKD patients
without a prior history of myocardial infarction or coronary
revascularization, whereas, in routine practice, coronary heart175
c l i n i ca l i nves t iga t i on I Schlackow et al.: Cost-effectiveness of statins/ezetimibe in CKDdisease is highly prevalent in people with moderate-to-
advanced CKD. Therefore, patients outside SHARP at
similar CKD stages are likely to be at higher cardiovascular
risk. However, the cost-effectiveness estimates corresponding
to categories of risk are likely to be generalizable to such
patients. Second, since SHARP did not directly assess the
effects of ezetimibe monotherapy in patients with CKD, we
incorporated an assumption that its effects on clinical out-
comes are equivalent, per mmol/L reduction in LDL choles-
terol, to those of statins. This assumption was derived from
the results of the CTT meta-analysis of the effects of statin-
based regimens at different levels of eGFR7 and by the
IMPROVE-IT trial, which was conducted in people with an
acute coronary syndrome treated with statin8 and demon-
strated further cardiovascular risk reductions with ezetimibe
similar to those with statin-only regimens achieving similar
LDL cholesterol reductions.9 Third, the effect of treatments
on non–health care costs, such as productivity or long-term
care costs, were not included in the present analysis, which
was conducted exclusively from a health services perspective.
Finally, safety of statin-based regimens has been a subject of
debate despite the acknowledgement that any adverse effects
are rare and beneﬁts strongly outweigh any harm.22,23 We did
not include adverse effects in our primary analysis due to the
paucity of data for different treatments. However, sensitivity
analyses incorporating estimated rates of potential adverse
effects on muscle (e.g., myopathy and rhabdomyolysis) and
diabetes yielded similar results.
In conclusion, statin-based treatments effectively reduce
cardiovascular risk in nondialysis patients with CKD and, at
current prices and cost-effectiveness thresholds, the available
evidence suggests that low-cost statin/ezetimibe combination
therapy is cost-effective. The most cost-effective regimen is
one that maximizes the dose of statin chosen without
compromising safety.METHODS
The SHARP CKD-CVD policy model
The SHARP CKD-CVD policy model, which is a Markov state-
transition model developed using the SHARP study6,18 data
and validated in 3 external CKD cohorts,17 was used to project
cardiovascular events, CKD progression, health care costs, and
health-related quality of life (QoL). A full description of the model
has been published elsewhere.17 Brieﬂy, it is based on parametric risk
equations (3 survival equations for cardiovascular outcomes, a
multinomial regression and a logistic regression for CKD progres-
sion, and 2 linear regressions predicting hospital costs and QoL).
Each equation includes a range of clinically and/or statistically
important covariates, including the patient’s sociodemographic sta-
tus, comorbidities, and risk factors (eg age, most recent CKD stage,
and detailed cardiovascular disease history.
The model simulates annual risks of dying from vascular
and nonvascular causes; experiencing a major atherosclerotic event
or a hemorrhagic stroke; and progressing through CKD stages 3B
(30 # eGFR <45 ml/min per 1.73m2), 4 (15 # eGFR <30 ml/min
per 1.73m2), and 5 (eGFR <15 ml/min per 1.73m2), or having
dialysis or kidney transplant (Supplementary Figure S2).176CKD patients
Results are presented only for the 6235 SHARP nondialysis patients
(since previous analyses have shown that lowering LDL cholesterol is
not clinically effective in dialysis patients7); all such patients had
moderate-to-advanced CKD (Table 1, Supplementary Table S1). At
baseline, the study participants were categorized according to their
CKD stage: (i) CKD stage 3B; (ii) CKD stage 4; or (iii) CKD stage 5
not on dialysis. They were also categorized by their 5-year risk of
major vascular event16: (i) low (<10%); (ii) medium
($10%, <20%); and (iii) high ($20%) risk. eGFR was calculated
using the CKD-EPI equation.24 The rates of nonvascular mortality
were obtained from relevant population data (see Supplementary
Table S11 for US rates and Schlackow et al.17 for UK rates).
Effects of statin/ezetimibe treatments
We considered a range of statin/ezetimibe regimens that are believed
to be safe in CKD, including ezetimibe 10 mg, atorvastatin 20 mg,
atorvastatin 40 mg, rosuvastatin 20 mg, simvastatin 20 mg plus
ezetimibe 10 mg, atorvastatin 20 mg plus ezetimibe 10 mg, and
atorvastatin 40 mg plus ezetimibe 10 mg daily. Treatment effects
were projected on the risks of vascular death and major vascular
events but not CKD progression25 or nonvascular mortality.6,7 For
each statin/ezetimibe regimen, the effects on vascular endpoints were
expressed as relative risk reductions and evaluated separately for each
CKD stage in 2 steps. First, the absolute reductions in LDL choles-
terol were calculated using the expected proportional reductions in
LDL cholesterol (Supplementary Table S2) and the mean LDL
cholesterol of the SHARP participants in the respective CKD stage
(Table 1, Supplementary Table S3). Second, these absolute reductions
were combined with the rate ratios for vascular events per 1 mmol/L
reduction in LDL cholesterol reported in the individual participant
data meta-analysis by the CTT Collaboration (Supplementary
Table S3).
Costs and QoL
Annual hospital costs of managing a patient with CKD and cardio-
vascular complications were based on published data (see
Supplementary Table S12 for the US costs and Kent et al.26 for the
UK costs) and inﬂated to year 2015 using the Consumer Price In-
dex27 (US) or Hospital & Community Health Services Index28 (UK).
The costs of statin and ezetimibe treatments (January 2019) were
obtained from the National Average Drug Acquisition Cost
(NADAC) reports29 (US) and NHS Electronic Drug Tariff30 (UK)
(Supplementary Table S2).
Patients’ health-related QoL was derived from responses to the
EuroQoL 5-dimensions 3-level (EQ-5D-3L) questionnaire31 completed
by participants at the ﬁnal SHARP follow-up visit and using the US32 or
UK33 EQ-5D-3L utility tariffs (see Supplementary Table S13 for US
estimates and Schlackow et al.17 for UK estimates) and stratiﬁed by
CKD stage, cardiovascular morbidity, and other characteristics.
Cost-effectiveness analyses
The cost-effectiveness analyses were performed from the per-
spectives of the US and UK health care systems. Health outcomes
and costs were projected with lifelong treatment with each statin/
ezetimibe regimen as well as no treatment, until patients reached
95 years of age or died. Costs and QALYs were discounted at an
annual rate of 3% (US34) or 3.5% (UK35). For each treatment, the
incremental cost-effectiveness ratios were calculated as the incre-
mental cost per QALY gained with the treatment against the next
less effective (and not dominated) treatment.36 Results areKidney International (2019) 96, 170–179
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rately, by cardiovascular risk at baseline. Uncertainty in the cost-
effectiveness was assessed using the nonparametric bootstrap,37
with the analysis replicated on 1000 sets of risk, cost, and QoL
parameter estimates derived from reﬁtting the original SHARP
CKD-CVD risk equations17 on bootstrapped SHARP data or, for
US hospital costs, using sampled values from the parametric dis-
tribution of costs (Supplementary Table S12).38 Uncertainty in the
treatment effects was incorporated using values sampled from the
respective lognormal distribution corresponding to the relative
risk (99% CI) reported by the CTT collaboration.7 Cost-
effectiveness acceptability curves were derived to summarize the
probability of each treatment being cost-effective at different levels
of willingness-to-pay thresholds.36
A schematic of our approach is presented in Supplementary
Figure S3.
Sensitivity analyses
First, sensitivity analyses were performed to assess robustness of the
results. The price of ezetimibe was varied from the current prices of
$0.203/d (US) and £0.074/d (UK) to the price of atorvastatin 40 mg
of $0.103/d (US) and £0.034/d (UK). The price at which ezetimibe
becomes cost-effective for the commonly used thresholds of
$100,000 (US) and £20,000 (UK) per QALY was calculated. Second,
to estimate the likely effect of dialysis costs on cost-effectiveness
results, the analyses were repeated with RRT costs replaced with
those for CKD stage 5 not on dialysis. Third, an analysis incorpo-
rating potential rare adverse effects of atorvastatin 40 mg alone or in
combination with ezetimibe 10 mg daily was performed. Speciﬁcally,
we assumed that during each year in patients taking atorvastatin 40
mg daily (with or without ezetimibe), 0.011% will experience
myopathy at a cost of $33 (£19; derived as the cost of 3 creatine
kinase tests) and 0.001 QoL decrement (i.e., 0.017 decrement over 30
days), and 0.0042% will experience rhabdomyolysis at a cost of
$13,600 (£8000), of whom 10% will die, with the rest experiencing a
3% QoL decrement (i.e., 50% decrement over 7.5 days of hospital-
ization followed by 20% decrement over 30 days of recovering) in the
year of the rhabdomyolysis,23,39 and 0.2% will develop diabetes.40
Finally, the effect of nonadherence to treatment was explored in
scenarios where, respectively, 40%, 60%, and 80% of the patients
were taking the medication.
All analyses were performed with R 3.4.141; the graphs were
produced with the ggplot2 plotting system.42APPENDIX
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T. Musliner (Merck Schering Plough, nonvoting), L. Agodoa, J. Armitage, Z.
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